Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Post by gojotv!on May 20, 2021 2:35pm
70 Views
Post# 33241506

Drolet chez MI3 reconnait la valeur des actions de StageZero

Drolet chez MI3 reconnait la valeur des actions de StageZeroL'analyste Drolet chez MI3 prend sa part de la compagnie, chef de file en detection du cancer.
Le nom "StageZero" signifie la capacit de leur technologie "Aristotle" dpister plusieurs cancers par prise sanguine avant meme que les tumeurs ne produisent des symptomes.
Cette dtection prcoce permet aux oncologistes d'intervenir plus tot, ce qui impacte fortement le succes des traitements et la possibilit de survie.
Aussi, leur lien synergique avec les tlcliniciens internationaux chez "Care Oncology" permettent de faire un suivi fficace aupres du patient.
L'ensemble de ses services produisent pour le patient une couverture complete oncologique scurisante, ce qui impacte positivement le succes des traitements.
Bonne chance tous les investisseurs!

<< Previous
Bullboard Posts
Next >>